# Section 11. 510(k) Summary

# 510(K) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR 807.92.

The Assigned 510(k) number is: K00732

1. Submitter's Identification: TaiDoc Technology Corporation 3F, 5F, No.127, Wugong 2nd Rd., Wugu Township, Taipei County, 248, Taiwan

# Correspondence:

Nicky Pan Regulatory Affairs Specialist Tel: $+ 8 8 6 - 2 { - } 6 6 2 5 { - } 8 1 8 8 \ \# 1 1 9 6$ . Fax: +886-2-6625-0288 Email: nicky@taidoc.com.tw

Date of submission: March 12, 2010

Device name:

Proprietary name: FORA G30a blood glucose monitoring system

Regulatory information:

A. Regulation section: 21 CFR 862.1345 Glucose Test System   
B. Classification: Class II   
C. Product Code: CGA, Glucose Oxidase, Glucose NBW, System, Test, Blood Glucose, Over The Counter   
D. Panel: Chemistry (75)

# 3.Intended Use:

The FORA G30a Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and the following alternative sites: the palm, the forearm, the upper-arm, the calf and the thigh. It is intended for use by healthcare professionals and people with diabetes mellitus at home as an aid in monitoring the effectiveness of diabetes control program. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

The alternative site testing in the FORA G30a Blood Glucose Monitoring System can be used only during steady-state blood glucose conditions.

# Device Description:

The system consists of three main products: the meter, test strips, and control solutions. These products have been designed, tested, and proven to work together as a system to produce accurate blood glucose test results. Use only FORA G30a test strips and control solutions with the FORA G30a Blood Glucose Monitoring System.

Substantial Equivalence Information:

A. Predicate device name:   
FORA G30 Blood Glucose Monitoring System   
B. Predicate K number: K090187   
C. Comparison with predicate:   
The modified FORA G30a blood glucose monitoring system has the following   
similarities to the predicate device: same operating principle, same fundamental scientific technology,   
$\bigstar$ incorporate the same basic circuit design,   
$\mathbf { \delta m }$ incorporate the same materials,   
$\blacktriangledown$ same shelf life   
$\downharpoonleft$ packaged using the same materials, and Manufactured by the same process.

The modifications encompass:

A modification in the software of the glucose meter Labeling change due to the software modification

Test Principle:

The detection and measurement of glucose in blood is by an electrochemical biosensor technology using glucose oxidase.

6Performance Characteristics:

FORA G30a blood glucose monitoring system has the same performance characteristics as the predicate device.

A comparison of system accuracy performance demonstrated that the FORA G30a blood glucose monitoring system and the currently marketed FORA G30 Blood Glucose Monitoring System (cleared under K090187) are substantially equivalent.

Software verification and validation testing confirmed that the performance, safety and effectiveness of the FORA G30a blood glucose monitoring system is equivalent to the predicate device.

# 7. Conclusion:

Based on the information provided in this submission, the FORA G30a blood glucose monitoring system is substantially equivalent to the predicate FORA G30 Blood Glucose Monitoring System.

TaiDoc Technology Corporation   
c/o Nicky Pan   
Regulatory Affairs Specialist   
3F, 5F, No. 127, Wugong $2 ^ { \mathfrak { n } \mathfrak { d } }$ Rd Wugu Township   
Taipei County, China (Taiwan) 248

Re: k100732 Trade name: FORA G30a Blood Glucose Monitoring System Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose Test System Regulatory Class: Class II Product Code: NBW, CGA Dated: June 10, 2010 Received: June 10, 2010

Dear Nicky Pan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for a√±inual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

![](images/d17cf4db3c81f9ecf7aa97c91578dd86c04ce1fe0dfbd3bff89ebca8f732d9fc.jpg)

Courtny C. Harper, Ph.D.   
Directr   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Section 8. Indications for Use

# Indications for Use

510(k) Number: k100732

Device Name: FORA G30a Blood Glucose Monitoring System

Indications for Use:

The FORA G30a Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and the following alternative sites: the palm, the forearm, the upper-arm, the calf and the thigh. It is intended for use by healthcare professionals and people with diabetes mellitus at home as an aid in monitoring the effectiveness of diabetes control program. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

The alternative site testing in the FORA G30a Blood Glucose Monitoring System can be used only during steady-state blood glucose conditions.

Prescription Use And/Or Over the Counter Use X (21 CFR Part 801 Subpart D) (21 CFR Part 801 Subpart C)

Concurence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/73be3992959fbfe949929eda0d21f4e9a479c0151cea0fc408c319261680ff08.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device Evaluation and Safety   
510(k) K100732

Page l of _1_